All In Biotech

Drug Trial Radar · NCT01863225

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia

Last checked: Nov 19, 2026Latest source record: May 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

May 2013

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
Collaborators
South Australian Health and Medical Research Institute
First posted
May 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.

Conditions

  • Dyslipidemia
  • Coronary Artery Disease

Interventions

  • RVX000222Drug

    capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days

  • RosuvastatinDrug

    20 mg daily, 28-42 days

  • AtorvastatinDrug

    40 mg daily, 28-42 days

  • RosuvastatinDrug

    40 mg daily, 28-42 days

  • AtorvastatinDrug

    80 mg daily, 28-42 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterization of the pharmacokinetics of RVX000222 capsule formulation in combination with either atorvastatin or rosuvastatin in patients with dyslipidemia.Time frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Adelaide Hospital / CMAX

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.